JP2021521267A5 - - Google Patents
Info
- Publication number
- JP2021521267A5 JP2021521267A5 JP2021501072A JP2021501072A JP2021521267A5 JP 2021521267 A5 JP2021521267 A5 JP 2021521267A5 JP 2021501072 A JP2021501072 A JP 2021501072A JP 2021501072 A JP2021501072 A JP 2021501072A JP 2021521267 A5 JP2021521267 A5 JP 2021521267A5
- Authority
- JP
- Japan
- Prior art keywords
- hvr
- amino acid
- acid sequence
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081096 | 2018-03-29 | ||
| CNPCT/CN2018/081096 | 2018-03-29 | ||
| PCT/CN2019/080496 WO2019185035A1 (en) | 2018-03-29 | 2019-03-29 | Anti-pd-l1 antibodies and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521267A JP2021521267A (ja) | 2021-08-26 |
| JP2021521267A5 true JP2021521267A5 (https=) | 2022-04-06 |
| JP7433285B2 JP7433285B2 (ja) | 2024-02-19 |
Family
ID=68060953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501072A Active JP7433285B2 (ja) | 2018-03-29 | 2019-03-29 | 抗ｐｄ－ｌ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12054548B2 (https=) |
| EP (1) | EP3774920A4 (https=) |
| JP (1) | JP7433285B2 (https=) |
| KR (1) | KR20210016514A (https=) |
| CN (2) | CN112424225B (https=) |
| AU (1) | AU2019241345A1 (https=) |
| CA (1) | CA3095076A1 (https=) |
| MY (1) | MY204733A (https=) |
| WO (1) | WO2019185035A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230303699A1 (en) * | 2020-08-04 | 2023-09-28 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
| BR112023016706A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| CN114225023B (zh) * | 2021-12-22 | 2022-10-18 | 宝船生物医药科技(上海)有限公司 | 抗csf-1r抗体联合抗pd-l1抗体的应用 |
| WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| WO2024107731A2 (en) * | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN106604742B (zh) * | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| UA126905C2 (uk) * | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Антитіло до pd-l1 та його застосування |
| CN110337448B (zh) * | 2016-12-23 | 2023-08-08 | 瑞美德生物医药科技有限公司 | 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 |
-
2019
- 2019-03-29 CA CA3095076A patent/CA3095076A1/en active Pending
- 2019-03-29 EP EP19778308.7A patent/EP3774920A4/en not_active Withdrawn
- 2019-03-29 CN CN201980023860.8A patent/CN112424225B/zh active Active
- 2019-03-29 AU AU2019241345A patent/AU2019241345A1/en not_active Abandoned
- 2019-03-29 JP JP2021501072A patent/JP7433285B2/ja active Active
- 2019-03-29 KR KR1020207030994A patent/KR20210016514A/ko active Pending
- 2019-03-29 MY MYPI2020005109A patent/MY204733A/en unknown
- 2019-03-29 CN CN202310883785.0A patent/CN117362436A/zh active Pending
- 2019-03-29 US US17/043,454 patent/US12054548B2/en active Active
- 2019-03-29 WO PCT/CN2019/080496 patent/WO2019185035A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521267A5 (https=) | ||
| JP7235256B2 (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP7173618B2 (ja) | アルファ－シヌクレインに対する抗体およびその用途 | |
| US20090041679A1 (en) | Human neutralizing monoclonal antibodies to h5n1 influenza a virus | |
| JP2021526022A5 (https=) | ||
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP2010526028A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| JP2019509737A5 (https=) | ||
| JP2020500003A5 (https=) | ||
| HRP20180083T1 (hr) | Terapija i dijagnoza tau-posredovanje patologije u alzheimerovoj bolesti zasnovana na proteinu | |
| JP2012512634A5 (https=) | ||
| JP2009541204A5 (https=) | ||
| CN115916256B (zh) | 抗SARS-CoV-2刺突蛋白抗体 | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| US20220119546A1 (en) | Plectin-1 binding antibodies and uses thereof | |
| JP2021523100A5 (https=) | ||
| JP2017507131A5 (https=) | ||
| JP2017538439A5 (https=) | ||
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| JP2014515600A5 (https=) | ||
| JP2025087764A5 (https=) | ||
| JP2009529915A5 (https=) | ||
| JP2018529328A5 (https=) |